IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer

• Published in: Molecular therapy. Oncolytics 2020-03, Vol.16, p.188-196
• Main Authors: Lee, Mi-Sook, Jung, Kyungsoo, Song, Ji-Young, Sung, Min-Jung, Ahn, Sung-Bin, Lee, Boram, Oh, Doo-Yi, Choi, Yoon-La
• Format: Article
• Language: English
• Subjects: Ceritinib; IRS2; patient-derived xenograft; PDX; SCLC; small cell lung cancer; targeted therapy
• ISSN: 2372-7705; 2372-7705
• DOI: 10.1016/j.omto.2019.12.009

Small cell lung cancer (SCLC) is a fast-growing and malignant cancer that responds well to chemotherapy; however, the survival rate is less than 15% after 2 years of diagnosis. Therefore, novel therapeutic agents for treating SCLC patients need to be evaluated. This study aims to identify the therapeutic targets based on the comprehensive genomic profiling of SCLC patients. Among the molecular-profiled SCLC samples obtained using targeted sequencing, the array-based comparative genomic hybridization (array CGH) identified focal insulin receptor substrate 2 (IRS2) amplification in the SCLC patients. IRS2 amplification was confirmed in 5% of 73 SCLC patients. To determine whether IRS2 amplification could act as a therapeutic target, we generated a patient-derived xenograft (PDX) model and subsequently screened 43 targeted agents using the PDX-derived cells (PDCs). Ceritinib significantly inhibited the cell growth and impaired the tumor sphere formation in IRS2-expressing PDCs. Its effects were confirmed in various in vitro assays and were further validated in the mouse xenograft models. In this study, we present that IRS2 amplification and/or expression serve as preclinical implications for a novel therapeutic target in SCLC progression. Furthermore, we suggest that insulin-like growth factor-1 (IGF-1) receptor inhibitor-based therapy could be used for treating SCLC with IRS2 amplification.